Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04270175 |
|
Recruitment Status :
Recruiting
First Posted : February 17, 2020
Last Update Posted : June 9, 2022
|
Sponsor:
Weill Medical College of Cornell University
Collaborator:
Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
Weill Medical College of Cornell University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 2024 |
| Estimated Study Completion Date : | February 2025 |